Jen Asher, Ph.D.

Founder & CEO @1910_AI

[Jen Asher, Ph.D. @jenasherphd]

What's better than one flagship AI publication? Two in the same year!

I enjoyed discussing 1910's latest AI models — PEGASUS™ for macrocyclic peptide design and CANDID-CNS™ for small molecule BBB penetration with @GENbio for @1910_ai

GEN Article here: https://t.co/6cz42NJ43O

[Jen Asher, Ph.D. @jenasherphd]

I'm thrilled to be speaking at @SynBioBeta, on a panel exploring the New AI Operating Model for Pharma Partnerships. I'll be representing @1910_ai alongside @chaidiscovery, @nablabio, @NOETIK_ai, @lifeschemistry, and @theinformation

#SynBioBeta2026, #AIxBio, #Partnerships

[1910 @1910_ai]

Learn more about 1910’s flagship AI models:

PEGASUS™ Featured Publication in J. Med. Chem.: https://t.co/7ZbGGob4Iz

CANDID-CNS™ Publication in JCIM: https://t.co/jD7vCBpF4Q

Read the media exclusive in GEN Edge: https://t.co/DtlPWhnaZ5

[Jen Asher, Ph.D. @jenasherphd]

Honored to be in the company of AI x Bio women I admire!

The future of frontier AI in Pharma is here, and @1910_ai is leading it!

[1910 @1910_ai]

Our founder @JenAsherPhD was featured in a spotlight on 5 women shaping AI x Bio — highlighting Jen's work at 1910, where we're building an AI-native biotech transforming drug discovery with our ITO™ Platform.

Read the article: https://t.co/MCFYhBLelA

[Jen Asher, Ph.D. @jenasherphd]

Great exclusive interview with @GENbio discussing the latest frontier AI models from @1910_ai -- PEGASUS™ for macrocyclic peptide design and CANDID-CNS™ for small molecule BBB penetration!

To partner, please contact [email protected]

[Genetic Engineering & Biotechnology News @GENbio]

1910 Unlocks Macrocyclic Peptide Drugs Using PEGASUS AI Model

PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill
@jenasherphd @1910_ai
#AI #drugdiscovery #peptides
https://t.co/AzWbtMmMxO

[Jen Asher, Ph.D. @jenasherphd]

Today, @1910_ai is thrilled to announce the publication of PEGASUS™, a state-of-the-art AI model for de novo design and optimization of macrocyclic peptides.

▪️Paper: https://t.co/cIJ0pacEZR
▪️Press Release: https://t.co/3nl91kUzGa
▪️ BD: To partner on PEGASUS™, [email protected]

[1910 @1910_ai]

▶️ Learn more about our ITO™ Platform, which integrates massive multimodal data, frontier AI models, and high-throughput lab automation to identify novel disease targets and design therapeutics better and faster than traditional approaches.

[Jen Asher, Ph.D. @jenasherphd]

@BronMuse D9,8p55

[Jen Asher, Ph.D. @jenasherphd]

- Press Release: https://t.co/7Y43xp2Fx6

- To partner with 1910 on CANDID-CNS™, please contact [email protected]

[Jen Asher, Ph.D. @jenasherphd]

Today, @1910_ai publishes CANDID-CNS™, a SOTA AI model that predicts BBB penetration by unlocking Beyond-Rule-of-5 (bRo5) chemical space and stereochemistry of small molecules.

- Paper: https://t.co/8gNa7sUOV4

[Jesse W. Collins @jeswcollins]

I'm excited to announce that @1910_ai's CANDID-CNS™ AI model is now published in the Journal of Chemical Information and Modeling (JCIM) @ACSPublications, marking an important milestone in validating AI-driven approaches to CNS drug discovery.

Paper: https://t.co/RWBQk2EeiL

[1910 @1910_ai]

Today, 1910 is thrilled to announce the publication of CANDID-CNS™, a state-of-the-art AI model that predicts BBB penetration by unlocking Beyond-Rule-of-5 (bRo5) chemical space and stereochemistry of small molecules.

[Jen Asher, Ph.D. @jenasherphd]

At today's #AIDDDSummit, AI in drug discovery is on full display. It's why we built @1910_ai's ITO™ platform —integrating massive multimodal data, frontier AI models, and high-throughput lab automation for AI-enabled drug discovery. Check it out at https://t.co/Q9RMooDrc8.

[1910 @1910_ai]

🧬 Introducing our ITO™ platform, which integrates massive multimodal data, frontier AI models, and high-throughput lab automation to identify novel disease targets and design small and large molecule therapeutics better and faster than traditional approaches.

[1910 @1910_ai]

We're entering a new chapter of transformative pharmaceutical partnerships and building a pipeline of innovative medicines. Watch to learn more from our Founder @JenAsherPhD about our new mission to Make Every Pharma Company an AI Company™.

[1910 @1910_ai]

We’ve got a new look to match our bold new mission. See more at https://t.co/ziNSGi9cA3

[Jen Asher, Ph.D. @jenasherphd]

1910 Genetics is now 1910.

We’re unveiling a reimagined brand that reflects our new mission to Make Every Pharma Company an AI Company™.

Join us in our new chapter. Visit our new website at https://t.co/SMNARhFusR.

cc: @1910_ai

[Joel Osteen @JoelOsteen]

When you don’t see a way out, help from heaven is coming. God knows how to speak to the right people. He knows how to keep you hidden from the enemy, how to rescue you from trouble, turn the sickness around, open doors you can’t open.

[Jen Asher, Ph.D. @jenasherphd]

@StockMKTNewz ..

[Jen Asher, Ph.D. @jenasherphd]

An absolute honor to speak on this panel at the first ever AI & Drug Discovery Symposium hosted by @goodwinlaw, and share our approach to Platform IP and BD partnering at @1910Genetics!

[1910 @1910_ai]

1910 CEO, @jenasherphd to speak on panel "Diligence Considerations with Tech Acquirers and IP Risks from #AI in Drug Discovery and Development" at @goodwinlaw #AI & #DrugDiscovery Symposium: Revolutionizing the Future of Medicine. Reg and details here:https://t.co/oTsJNHXuX0